|1.||Papalois, Apostolos: 7 articles (07/2015 - 09/2003)|
|2.||Papalois, Apostolos E: 4 articles (09/2015 - 04/2014)|
|3.||Agrogiannis, George: 4 articles (03/2015 - 04/2014)|
|4.||Liapi, Charis: 3 articles (07/2015 - 06/2012)|
|5.||Bimpis, Alexios: 3 articles (07/2015 - 06/2012)|
|6.||Patsouris, Efstratios S: 3 articles (03/2015 - 04/2014)|
|7.||Flessas, Ioannis: 3 articles (03/2015 - 04/2014)|
|8.||Toutouzas, Konstantinos: 2 articles (09/2015 - 01/2015)|
|9.||Psaltopoulou, Theodora: 2 articles (03/2015 - 04/2014)|
|10.||Zagouri, Flora: 2 articles (03/2015 - 04/2014)|
04/01/1999 - "Early cardiac function following Tx was significantly better and histological damage was less in the Lazaroid-treated group than in the control group, suggesting that Lazaroid U-74389G is effective in preventing ischemia-reperfusion injury after preservation and Tx."
04/01/1999 - "To investigate the role of eicosanoid generation and neutrophilic infiltration in the protective effects of U74389F against ischemia/reperfusion injury in the small intestines of rats. "
11/01/1998 - "Lazaroid U-74389G ameliorates ischemia-reperfusion injury in canine hearts: a histologic study."
11/01/1999 - "Lazaroid U-74389G ameliorates ischemia-reperfusion injury caused by Pringle's procedure during extensive liver resection. "
06/01/1995 - "Improved survival and reversal of endothelial dysfunction by the 21-aminosteroid, U-74389G in splanchnic ischaemia-reperfusion injury in the rat."
03/01/2015 - "This swine model of pancreatic ischemia and reperfusion, encompassing preconditioning, indicates that U-74389G lazaroid does not seem to exert protective effects from pancreatic damage."
11/01/1994 - "We conclude that whereas SOD was detrimental, the lazaroid analogue U-74389F improved microvascular perfusion following 3 h of no-flow ischemia and 90 min reperfusion."
03/01/2015 - "The present study focuses specifically on the pancreas and aims to examine any effects of U-74389G in a swine model of pancreatic ischemia and reperfusion, encompassing ischemic preconditioning. "
04/01/2014 - "The aim of our study was to evaluate the therapeutic potential of 21-aminosteroid U-74389G in pancreatic injury after ischemia and reperfusion of the organ in a swine model. "
01/01/2014 - "The aim of this experiment was to study the effects of the antioxidant drug "U-74389G" on rat model, particularly in ischemia reperfusion protocol. "
02/01/1998 - "Protective effects of the lazaroid U-74389G against hyperoxia in rat type II pneumocytes."
01/01/1993 - "However, U-74389F did not inhibit the hyperoxia-induced accumulation of neutrophils in bronchoalveolar lavage fluid. "
03/16/1998 - "Administration of U-74389G offers some degree of protection against hyperoxia and attenuation of these biomarkers of oxidation, but the precise mechanisms by which this protection is effected will require additional study."
02/01/1998 - "The aims of this study were to investigate the effect of hyperoxia on O2(-.), H2O2 and .NO generation and iNOS mRNA levels in rat type II pneumocytes in vitro and the possible protective effect of the lazaroid U-74389G. "
07/01/1997 - "The aim of the study was to investigate (1) the effects of in vitro hyperoxia on gamma-GT activity of type II cells and (2) the effects of the lazaroid U-74389G and N-acetylcysteine (NAC) on the hyperoxia-induced changes in gamma-GT and antioxidant enzyme activities. "
|4.||Brain Ischemia (Cerebral Ischemia)
01/01/1997 - "These results are in agreement with the neuroprotective efficacy of desmethyl tirilazad in cerebral ischemia."
03/01/1996 - "The present study revealed that U-74389G attenuated delayed neuronal death in global cerebral ischemia when it was administered before or soon after the ischemic episode."
03/01/1996 - "Therapeutic time window for the 21-aminosteroid, U-74389G, in global cerebral ischemia."
01/01/1997 - "In our current study the neuroprotective potential of the 21-aminosteroid U-74389G was compared with that of the pyrrolopyrimidine U-101033E in a rat model of reversible focal cerebral ischemia. "
10/01/1998 - "Pretreatment with desmethyl tirilazad or dizocilpine maleate or nimodipine individually significantly suppressed (p < 0.01) the increase in cNOS activity and cGMP levels induced by cerebral ischemia, which may be related to their neuroprotective effect. "
04/01/1998 - "Protection by the 21-aminosteroid at normothermic conditions, or additional protection when U-74389G was added to mild hypothermia, could not be demonstrated."
04/01/1998 - "Forty male anesthetized New Zealand white rabbits were randomized to four groups (n = 10): (a) normothermia (control); (b) U-74389G (3 mg/kg intravenously [i.v.] before aortic occlusion, 1.5 mg/kg i.v. and 10 mg/kg intraperitoneally after occlusion); (c) mild hypothermia (4 degrees C epidural temperature decrease); and (d) mild hypothermia combined with U-74389G. "
03/01/1996 - "Treatment with moderate hypothermia (32 degrees C for 4 h), a 21-aminosteroid (U-74389G, Upjohn, 10 mg/kg intravenously, repeated 3 h after the first dose), or both, was initiated 10, 25, or 40 min after injury. "
04/01/1998 - "In this study we compared the effects of mild hypothermia and the 21-aminosteroid U-74389G, alone and in combination on neurologic and histopathologic outcome after temporary spinal cord ischemia. "
04/01/1998 - "Effect of mild hypothermia and the 21-aminosteroid U-74389G on neurologic and histopathologic outcome after transient spinal cord ischemia in the rabbit."
|1.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|3.||U 101033E (U-101033E)
|4.||Biological Markers (Surrogate Marker)
|6.||Edetic Acid (EDTA)
|7.||glucuronyl glucosamine glycan sulfate (Vessel)
|2.||Surgical Instruments (Clip)
|3.||Heart Transplantation (Grafting, Heart)